GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NuVasive Inc (NAS:NUVA) » Definitions » Asset Turnover

NuVasive (NuVasive) Asset Turnover : 0.15 (As of Jun. 2023)


View and export this data going back to 2004. Start your Free Trial

What is NuVasive Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. NuVasive's Revenue for the three months ended in Jun. 2023 was $318 Mil. NuVasive's Total Assets for the quarter that ended in Jun. 2023 was $2,128 Mil. Therefore, NuVasive's Asset Turnover for the quarter that ended in Jun. 2023 was 0.15.

Asset Turnover is linked to ROE % through Du Pont Formula. NuVasive's annualized ROE % for the quarter that ended in Jun. 2023 was 3.34%. It is also linked to ROA % through Du Pont Formula. NuVasive's annualized ROA % for the quarter that ended in Jun. 2023 was 1.38%.


NuVasive Asset Turnover Historical Data

The historical data trend for NuVasive's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NuVasive Asset Turnover Chart

NuVasive Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.66 0.65 0.46 0.47 0.55

NuVasive Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.14 0.14 0.14 0.15

Competitive Comparison of NuVasive's Asset Turnover

For the Medical Devices subindustry, NuVasive's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NuVasive's Asset Turnover Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NuVasive's Asset Turnover distribution charts can be found below:

* The bar in red indicates where NuVasive's Asset Turnover falls into.



NuVasive Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

NuVasive's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=1201.942/( (2154.075+2224.505)/ 2 )
=1201.942/2189.29
=0.55

NuVasive's Asset Turnover for the quarter that ended in Jun. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2023 )/( (Total Assets (Q: Mar. 2023 )+Total Assets (Q: Jun. 2023 ))/ count )
=317.786/( (2167.154+2089.55)/ 2 )
=317.786/2128.352
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


NuVasive  (NAS:NUVA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

NuVasive's annulized ROE % for the quarter that ended in Jun. 2023 is

ROE %**(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=29.456/883.1115
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(29.456 / 1271.144)*(1271.144 / 2128.352)*(2128.352/ 883.1115)
=Net Margin %*Asset Turnover*Equity Multiplier
=2.32 %*0.5972*2.4101
=ROA %*Equity Multiplier
=1.38 %*2.4101
=3.34 %

Note: The Net Income data used here is four times the quarterly (Jun. 2023) net income data. The Revenue data used here is four times the quarterly (Jun. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

NuVasive's annulized ROA % for the quarter that ended in Jun. 2023 is

ROA %(Q: Jun. 2023 )
=Net Income/Total Assets
=29.456/2128.352
=(Net Income / Revenue)*(Revenue / Total Assets)
=(29.456 / 1271.144)*(1271.144 / 2128.352)
=Net Margin %*Asset Turnover
=2.32 %*0.5972
=1.38 %

Note: The Net Income data used here is four times the quarterly (Jun. 2023) net income data. The Revenue data used here is four times the quarterly (Jun. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


NuVasive Asset Turnover Related Terms

Thank you for viewing the detailed overview of NuVasive's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


NuVasive (NuVasive) Business Description

Traded in Other Exchanges
N/A
Address
12101 Airport Way, Broomfield, CO, USA, 92121
NuVasive Inc is a medical technology company focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. The company has a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. It also develop and sell magnetically adjustable implant systems for spine and specialized orthopedic procedures.
Executives
Michael Farrington officer: SVP, People and Culture 7475 LUSK BLVD., SAN DIEGO CA 92121
Marc W. Rosenbaum officer: Chief Accounting Officer 7475 LUSK BLVD., SAN DIEGO CA 92121
James Christopher Barry director, officer: Chief Executive Officer 7475 LUSK BLVD, SAN DIEGO CA 92121
Andrew C. Morton officer: SVP, CHRO 10910 DOMAIN DRIVE, SUITE 300, AUSTIN TX 78758
Amy Belt Raimundo director ONE KAISER PLAZA, 22ND FLOOR, OAKLAND CA 94612
Lucas Vitale officer: Chief Human Resources Officer 7475 LUSK BLVD, SAN DIEGO CA 92121
Massimo Calafiore officer: EVP, Global Business Units 7475 LUSK BLVD., SAN DIEGO CA 92121
Siddhartha Kadia director 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Brent J. Boucher officer: EVP, Global Commercial 14 PLAZA DRIVE, LATHAM NY 12110
Matthew Link officer: Exec. VP U.S. Sales 7475 LUSK BLVD, SAN DIEGO CA 92121
Matthew K Harbaugh officer: EVP and CFO 675 MCDONNELL BLVD., HAZELWOOD MO 63042
Dale A. Wolf officer: SVP, Global Operations 7475 LUSK BLVD., SAN DIEGO CA 92121
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Mcclintock officer: President, U.S. Commercial 7475 LUSK BLVD, SAN DIEGO CA 92121

NuVasive (NuVasive) Headlines

From GuruFocus